Stefanie Mullins

机构：AstraZeneca (United Kingdom), F-star (United Kingdom) · ORCID：0000-0003-4433-2288

发表论文 55 篇 · 总被引 2642 次 · h-index 17

代表论文

• Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery (2016 · Cancer Immunology Research · 被引 442)
• Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody (2015 · Cancer Immunology Research · 被引 416)
• FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells (2011 · BMC Cancer · 被引 305)
• Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies (2019 · Journal for ImmunoTherapy of Cancer · 被引 207)
• Photodynamic Molecular Beacon Triggered by Fibroblast Activation Protein on Cancer-Associated Fibroblasts for Diagnosis and Treatment of Epithelial Cancers (2008 · Journal of Medicinal Chemistry · 被引 107)
• Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model (2016 · Oncotarget · 被引 99)